Cargando…

Prevalence, incidence and survival of smoldering multiple myeloma in the United States

Detalles Bibliográficos
Autores principales:	Ravindran, A, Bartley, A C, Holton, S J, Gonsalves, W I, Kapoor, P, Siddiqui, M A, Hashmi, S K, Marshall, A L, Ashrani, A A, Dispenzieri, A, Kyle, R A, Rajkumar, S V, Go, R S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098258/ https://www.ncbi.nlm.nih.gov/pubmed/27768092 http://dx.doi.org/10.1038/bcj.2016.100

Ejemplares similares

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy
por: Siontis, B, et al.
Publicado: (2015)

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Amyloid arthropathy in smoldering myeloma: Do not take it lightly
por: Muchtar, Eli, et al.
Publicado: (2021)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2012)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
por: Gonsalves, W I, et al.
Publicado: (2015)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
por: Hwa, Yi L., et al.
Publicado: (2016)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
por: Binder, M, et al.
Publicado: (2016)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Recent Advances in the Management of Smoldering Multiple Myeloma
por: Madhira, Bhaskara Reddy, et al.
Publicado: (2020)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
por: Zanelli, Magda, et al.
Publicado: (2021)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
por: Lussier, Tyler, et al.
Publicado: (2021)

Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion
por: Jhaveri, A., et al.
Publicado: (2010)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
por: Markus, Efrat, et al.
Publicado: (2020)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case
por: Ghanem, Sassine, et al.
Publicado: (2016)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis
por: Bouattour, Nadia, et al.
Publicado: (2020)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
por: Ravi, Praful, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oevg3mvtei35i0986l320lhvh4